ReviewBiomarker research2020
Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions.
Review in Biomarker research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Probiotics treatment for Parkinson disease: a systematic review and meta-analysis of clinical trials.Aging · 2022Pooled it
- Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions.Frontiers in pharmacology · 2022Pooled it
- Review
- Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eµ-TCL1 mice.Frontiers in oncology · 2026Article
- Review
- Dietary yeast culture improves growth performance and nutrient utilization while reducing odor-causing compounds and modulating cecal microbiota in broilers.Frontiers in veterinary science · 2026Article
- Discovery and characterization of antitumor gut microbiota from amphibians and reptiles:Gut microbes · 2025Article
- Emerging multifaceted roles of the microbiome in cancer susceptibility.World journal of clinical oncology · 2025Review
- Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia.Cancer research communications · 2025Article
- Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast Cancer.International journal of molecular sciences · 2025Article
- Higher Microbial Abundance and Diversity in Bronchus-Associated Lymphoid Tissue Lymphomas Than in Non-cancerous Lung Tissues.Cancer research and treatment · 2025Article
- Article
- Gut microbiota - bidirectional modulator: role in inflammatory bowel disease and colorectal cancer.Frontiers in immunology · 2025Review
- Novel TLR2 agonist Amuc_C derived fromAnimal cells and systems · 2025Article
- [Causal relationship between gut microbiota and pigmented villonodular synovitis: a Mendelian randomization analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson's Disease Treatment?Cells · 2024Review
- Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer.International journal of molecular sciences · 2024Review
- Impact of Pulmonary microbiota on lung cancer treatment-related pneumonia.Journal of Cancer · 2024Article
- Affinity- and activity-based probes synthesized from structurally diverse hops-derived xanthohumol flavonoids reveal highly varied protein profiling inRSC advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota composition influences the balance between human health and disease. Increasing evidence suggests the involvement of microbial factors in regulating cancer development, progression, and therapeutic response. Distinct microbial species have been implicated in modulating gut environment and architecture that affects cancer therapy outcomes. While some microbial species offer enhanced cancer therapy response, others diminish cancer treatment efficacy. In addition, use of antibiotics, often to minimize infection risks in cancer, causes intestinal dysbiosis and proves detrimental. In this review we discuss the role of gut microbiota in cancer development and therapy. We also provide insights into future strategies to manipulate the microbiome and gut epithelial barrier to augment therapeutic responses while minimizing toxicity or infection risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.